Leiden, September 3 – We are thrilled to announce that GenLumina has secured funding from Health~Holland to support a collaborative project with LUMC. This grant will enable us to accelerate the development of our light-activated cancer therapy by expanding our laboratory capabilities and advancing preclinical research together with LUMC.

Within this collaboration, LUMC will develop a peptide that specifically targets colorectal cancer cells. By combining this peptide with GenLumina’s light-activated payload, we can develop a therapy that is both highly targeted and highly effective. This approach offers a powerful advantage over current treatments such as chemotherapy and radiation, which often damage healthy tissue and can cause severe side effects. In contrast, the combination of GenLumina’s payload with LUMC’s peptide is designed to directly target tumor cells while sparing healthy ones, enabling treatment that is safer, more precise and less invasive.

With the support of Health~Holland, we can strengthen our scientific foundation, build strategic partnerships and continue pursuing our mission: delivering safe, effective and precise cancer therapies that improve the lives of patients worldwide.

About Health Holland
Health Holland is the brand name of the Top Sector Life Sciences & Health (LSH). It stimulates public-private partnerships, invests in research and innovation, and strengthens the Dutch life sciences and health ecosystem to improve health and care both nationally and internationally.